Page 110 - Read Online

Page 12 of 13 Mauri et al. Mini-invasive Surg 2022;6:49 https://dx.doi.org/10.20517/2574-1225.2022.34

EVOLUT low risk sub-study. J Am Coll Cardiol 2020;75:2430-42. DOI PubMed
11. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic
valves: an observational study. The Lancet 2017;389:2383-92. DOI PubMed
12. Généreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter
aortic valve replacement. J Am Coll Cardiol 2014;64:2605-15. DOI PubMed
13. Makkar RR, Fontana GP, Jilaihawi H, et al; PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable
severe aortic stenosis. N Engl J Med 2012;366:1696-704. DOI PubMed
14. Mack MJ, Leon MB, Thourani VH, et al; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-
expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705. DOI PubMed
15. Piccolo R, Pilgrim T, Franzone A, et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among
patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:1436-46. DOI PubMed
16. Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve
implantation. Am J Cardiol 2018;122:310-5. DOI PubMed
17. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following
transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following
Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357-65. DOI PubMed
18. Raheja H, Garg A, Goel S, et al. Comparison of single versus dual antiplatelet therapy after TAVR: a systematic review and meta-
analysis. Catheter Cardiovasc Interv 2018;92:783-91. DOI PubMed
19. Sherwood MW, Xiang K, Matsouaka R, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding
complications in patients undergoing transfemoral transcatheter aortic valve replacement: insights from the society of thoracic
surgeons/American college of cardiology transcatheter valve therapies registry. Circ Cardiovasc Interv 2020;13:e008227. DOI
PubMed
20. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve
implantation. Am J Cardiol 2011;108:1772-6. DOI PubMed
21. Siddamsetti S, Balasubramanian S, Yandrapalli S, et al. Meta-analysis comparing dual antiplatelet therapy versus single antiplatelet
therapy following transcatheter aortic valve implantation. Am J Cardiol 2018;122:1401-8. DOI PubMed
22. Al Halabi S, Newman J, Farkouh ME, et al. Meta-analysis of studies comparing dual- versus mono-antiplatelet therapy following
transcatheter aortic valve implantation. Am J Cardiol 2018;122:141-8. DOI PubMed
23. Nijenhuis VJ, Ten Berg JM, Hengstenberg C, et al. Usefulness of clopidogrel loading in patients who underwent transcatheter aortic
valve implantation (from the BRAVO-3 Randomized Trial). Am J Cardiol 2019;123:1494-500. DOI PubMed
24. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J
Med 2020;383:1447-57. DOI PubMed
25. Dangas GD, Tijssen JGP, Wöhrle J, et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve
replacement. N Engl J Med 2020;382:120-9. DOI PubMed
26. Collet JP, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the
randomized ATLANTIS trial. Am Heart J 2018;200:44-50. DOI PubMed
27. Collet JP. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am
Heart J 2018;200:44-50. DOI PubMed
28. Rogers T, Shults C, Torguson R, et al. Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-
risk patients. Circ Cardiovasc Interv 2021;14:e009983. DOI PubMed
29. Brinkert M, Mangner N, Moriyama N, et al. Safety and efficacy of transcatheter aortic valve replacement with continuation of vitamin
k antagonists or direct oral anticoagulants. JACC Cardiovasc Interv 2021;14:135-44. DOI PubMed
30. Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating
patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2016;9:1706-17. DOI
PubMed
31. Geis NA, Kiriakou C, Chorianopoulos E, Pleger ST, Katus HA, Bekeredjian R. Feasibility and safety of vitamin K antagonist
monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017;12:2058-66. DOI
PubMed
32. Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC monotherapy in patients with concomitant
indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol 2018;107:799-806. DOI
PubMed
33. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N
Engl J Med 2020;382:1696-707. DOI PubMed
34. Didier R, Lhermusier T, Auffret V, et al; STOP-AS and France-TAVI. TAVR patients requiring anticoagulation: direct oral
anticoagulant or vitamin k antagonist? JACC Cardiovasc Interv 2021;14:1704-13. DOI PubMed
35. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin k antagonist for atrial fibrillation after TAVR. N
Engl J Med 2021;385:2150-60. DOI PubMed
36. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC
Cardiovasc Interv 2019;12:1566-76. DOI PubMed